12 Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Role of Abbott Laboratories in Global Oncology Precision Medicine Market
12.1.3 Financials
12.1.4 SWOT Analysis
12.2 Agilent Technologies, Inc.
12.2.1 Company Overview
12.2.2 Role of Agilent Technologies, Inc. in Global Oncology Precision Medicine Market
12.2.3 Financials
12.2.4 SWOT Analysis
12.3 Almac Group Ltd.
12.3.1 Company Overview
12.3.2 Role of Almac Group Ltd. in Global Oncology Precision Medicine Market
12.3.3 SWOT Analysis
12.4 ANGLE plc
12.4.1 Company Overview
12.4.2 Role of ANGLE plc in the Global Oncology Precision Medicine Market
12.4.3 Financials
12.4.4 Key Insights About Financial Health of the Company
12.4.5 SWOT Analysis
12.5 ASURAGEN INC.
12.5.1 Company Overview
12.5.2 Role of ASURAGEN Inc. in Global Oncology Precision Medicine Market
12.5.3 SWOT Analysis
12.6 BGI Group
12.6.1 Company Overview
12.6.2 Role of BGI Group in Global Oncology Precision Medicine Market
12.6.3 SWOT Analysis
12.7 Bio-Rad Laboratories, Inc.
12.7.1 Company Overview
12.7.2 Role of Bio-Rad Laboratories, Inc.in Global Oncology Precision Medicine Market
12.7.3 Financials
12.7.4 SWOT Analysis
12.8 bioMérieux S.A.
12.8.1 Company Overview
12.8.2 Role of bioMérieux SA. in Global Oncology Precision Medicine Market
12.8.3 Financials
12.8.4 SWOT Analysis
12.9 Bristol-Myers Squibb Company
12.9.1 Company Overview
12.9.2 Role of Bristol-Myers Squibb Company in Global Oncology Precision Medicine Market
12.9.3 Financials
12.9.4 SWOT Analysis
12.1 F. Hoffmann-La Roche Ltd
12.10.1 Company Overview
12.10.2 Role of F. Hoffman-LA Roche Ltd in Global Oncology Precision Medicine Market
12.10.3 Financials
12.10.4 SWOT Analysis
12.11 Gilead Sciences, Inc.
12.11.1 Company Overview
12.11.2 Role of Gilead Sciences, Inc. in Global Oncology Precision Medicine Market
12.11.3 Financials
12.11.4 SWOT Analysis
12.12 Illumina, Inc.
12.12.1 Company Overview
12.12.2 Role of Illumina, Inc. in Global Oncology Precision Medicine Market
12.12.3 Financials
12.12.4 SWOT Analysis
12.13 Konica Minolta, Inc.
12.13.1 Company Overview
12.13.2 Role of Konica Minolta, Inc. in Global Oncology Precision Medicine Market
12.13.3 Financials
12.13.4 SWOT Analysis
12.14 Laboratory Corporation of America Holdings
12.14.1 Company Overview
12.14.2 Role of Laboratory Corporation of America Holdings in Global Oncology Precision Medicine Market
12.14.3 Financials
12.14.4 SWOT Analysis
12.15 MDx Health, Inc.
12.15.1 Company Overview
12.15.2 Role of MDx Health, Inc. in the Global Precision Medicine Market
12.15.3 Financials
12.15.4 SWOT Analysis
12.16 Myriad Genetics, Inc
12.16.1 Company Overview
12.16.2 Role of Myriad Genetics, Inc. in the Global Oncology Precision Medicine Market
12.16.3 Financials
12.16.4 Key Insights About Financial Health of the Company
12.16.5 SWOT Analysis
12.17 Novartis AG
12.17.1 Company overview
12.17.2 Role of Novartis AG in the Global Oncology Precision Medicine Market
12.17.3 Financials
12.17.4 Key Insights About Financial Health of the Company
12.17.5 SWOT Analysis
12.18 OPKO Health, Inc.
12.18.1 Company Overview
12.18.2 Role of OPKO Health, Inc. in Global Oncology Precision Medicine Market
12.18.3 Financials
12.18.4 SWOT Analysis
12.19 Pacific Biosciences of California, Inc.
12.19.1 Company Overview
12.19.2 Role of Pacific Biosciences of California, Inc. in the Global Oncology Precision Medicine Market
12.19.3 Financials
12.19.4 Key Insights About Financial Health of the Company
12.19.5 SWOT Analysis
12.2 Quest Diagnostics
12.20.1 Company Overview
12.20.2 Role of Quest Diagnostics in Global Oncology Precision Medicine Market
12.20.3 Financials
12.20.4 SWOT Analysis
12.21 QIAGEN N.V.*
12.21.1 Company Overview
12.21.2 Role of QIAGEN N.V. in Global Oncology Precision Medicine Market
12.21.3 Financials
12.21.4 SWOT Analysis
12.22 Thermo Fisher Scientific Inc.
12.22.1 Company Overview
12.22.2 Role of Thermo Fisher Scientific Inc. in Global Oncology Precision Medicine Market
12.22.3 Financials
12.22.4 SWOT Analysis
List of Figures
Figure 1: Overall Deaths due to Key Cancer Causes, in Millions, (2012-2019)
Figure 2: Global Oncology Precision Medicine Market, 2019-2030
Figure 3: Market Drivers, Opportunities, and Restraints
Figure 4: Share of Key Developments and Strategies, January 2016-November 2020
Figure 5: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
Figure 6: Global Oncology Precision Medicine Applications Market Share (Application Type), 2019-2030
Figure 7: Global Oncology Precision Medicine Market (by Region)
Figure 2.1: Global Oncology Precision Medicine Market Segmentation
Figure 3.1: Global Oncology Precision Medicine Market Research Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Share of Total Number of Companies Profiled
Figure 4.1: Global Oncology Precision Medicine Market, 2019-2030
Figure 4.2: Evolution of Precision Medicine Technology
Figure 4.3: Molecular Diagnostics in Oncology
Figure 5.1: Number of Cancer Cases Diagnosed in the Netherlands (January 3, 2020, to April 12, 2020)
Figure 5.2: Pre-COVID-19 and Post-COVID-19 Scenario of Global Oncology Precision Medicine Market, 2017-2025
Figure 5.3: Areas of Disruption in Clinical Development
Figure 5.4: Measure to Navigate Crisis Recovery
Figure 6.1: FDA Guidelines for CDx Approval
Figure 6.2: Share of Patents Assigned (2015-2019)
Figure 6.3: Total Number of Patents Assigned to Key Technologies, 2016-2018
Figure 7.1: Impact Analysis of Market Dynamics
Figure 7.2: Rising Incidences of Cancer (2015 and 2018)
Figure 7.3: Estimated Cancer Incidences (Region-Wise), 2018 and 2040
Figure 7.4: Variable Outcomes of Pharmacologically Active Oncology Drugs and Prodrugs
Figure 7.5: Role of Biomarkers in Different Stages of Cancer
Figure 7.6: Significance of Biomarker on Treatment Monitoring
Figure 8.1: Share of Key Developments and Strategies, January 2016-November 2020
Figure 8.2: Share of Product Offerings, January 2016-August 2020
Figure 8.3: Share of Synergistic Activities, January 2016-August 2020
Figure 8.4: Share of Regulatory and Legal, January 2016-August 2020
Figure 8.5: Share of Mergers and Acquisitions, January 2016-August 2020
Figure 8.6: Share of Mergers and Acquisitions, January 2016-August 2020
Figure 8.7: Market Share Analysis: Global Oncology Precision Medicine Market, 2019
Figure 8.8: Growth-Share Matrix for Global Oncology Precision Medicine Market (by Company), 2019
Figure 9.1: Global Oncology Precision Medicine Market Share (by Application Type), 2019-2030
Figure 9.2: Global Oncology Precision Medicine Market (by Breast Cancer), 2019-2030
Figure 9.3: Global Oncology Precision Medicine Market (by Lung Cancer), 2019-2030
Figure 9.4: Global Oncology Precision Medicine Market (by Colorectal Cancer), 2019-2030
Figure 9.5: Global Oncology Precision Medicine Market (by Prostate Cancer), 2019-2030
Figure 9.6: Global Oncology Precision Medicine Market (by Cervical Cancer), 2019-2030
Figure 9.7: Global Oncology Precision Medicine Market (by Other Cancer), 2019-2030
Figure 10.1: Global Oncology Precision Medicine Market (by Ecosystem)
Figure 10.2: Precision Medicine: The Ecosystem
Figure 10.3: Global Oncology Precision Medicine Market (by Applied Sciences)
Figure 10.4: Global Oncology Precision Medicine Market (by Applied Sciences), 2019-2030
Figure 10.5: Global Oncology Precision Medicine Applied Sciences Market Share (by Type), 2019-2030
Figure 10.6: Global Oncology Precision Medicine Genomics Market, 2019-2030
Figure 10.7: Global Oncology Precision Medicine Genomics Market Share (by Technology)
Figure 10.8: Global Oncology Precision Medicine PCR Market, 2019-2030
Figure 10.9: Global Oncology Precision Medicine NGS Market, 2019-2030
Figure 10.10: Global Oncology Precision Medicine Genome Editing Market, 2019-2030
Figure 10.11: Global Oncology Precision Medicine Other Technologies Market, 2019-2030
Figure 10.12: Global Oncology Precision Medicine Pharmacogenomics Market, 2019-2030
Figure 10.13: Global Oncology Precision Medicine Other Applied Sciences Market, 2019-2030
Figure 10.14: Global Oncology Precision Medicine Market (by Precision Diagnostics)
Figure 10.15: Global Oncology Precision Medicine Market (by Precision Diagnostics), 2019-2030
Figure 10.16: Global Oncology Precision Medicine Diagnostics Market Share (by Type), 2019-2030
Figure 10.17: Global Oncology Precision Medicine Molecular Diagnostics Market, 2019-2030
Figure 10.18: Global Oncology Precision Medicine Medical Imaging Market, 2019-2030
Figure 10.19: Global Oncology Precision Medicine Digital Health and Information Technology Market, 2019-2030
Figure 10.20: Global Oncology Precision Medicine Digital Health and Information Technology Market Share (by Type), 2019-2030
Figure 10.21: Global Oncology Precision Medicine CDSS Market, 2019-2030
Figure 10.22: Global Oncology Precision Medicine Big Data Analytics Market, 2019-2030
Figure 10.23: Global Oncology Precision Medicine IT Infrastructure Market, 2019-2030
Figure 10.24: Global Oncology Precision Medicine Genomics Informatics Market, 2019-2030
Figure 10.25: Global Oncology Precision Medicine In-Silico Informatics Market, 2019-2030
Figure 10.26: Global Oncology Precision Medicine Mobile Health Market, 2019-2030
Figure 10.27: Global Oncology Precision Medicine Therapeutics Market, 2019-2030
Figure 10.28: Global Oncology Precision Medicine Therapeutics Market Share (by Type), 2019-2030
Figure 10.29: Global Oncology Precision Medicine Clinical Trials Market, 2019-2030
Figure 10.30: Global Oncology Precision Medicine Cell Therapy Market, 2019-2030
Figure 10.31: Global Oncology Precision Medicine Drug Discovery and Research Market, 2019-2030
Figure 10.32: Types of Gene Therapy
Figure 10.33: Global Oncology Precision Medicine Gene Therapy Market, 2019-2030
Figure 11.1: Global Oncology Precision Medicine Market (by Region)
Figure 11.2: North America Global Oncology Precision Medicine Market, 2019-2030
Figure 11.3: North America: Market Dynamics
Figure 11.4: North America Global Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.5: U.S. Oncology Precision Medicine Market, 2019-2030
Figure 11.6: Canada Oncology Precision Medicine Market, 2019-2030
Figure 11.7: Europe Oncology Precision Medicine Market, 2019-2030
Figure 11.8: Europe: Market Dynamics
Figure 11.9: Europe Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.10: Germany Oncology Precision Medicine Market, 2019-2030
Figure 11.11: France Oncology Precision Medicine Market, 2019-2030
Figure 11.12: Italy Oncology Precision Medicine Market, 2019-2030
Figure 11.13: U.K. Oncology Precision Medicine Market, 2019-2030
Figure 11.14: Spain Oncology Precision Medicine Market, 2019-2030
Figure 11.15: Rest-of-Europe Oncology Precision Medicine Market, 2019-2030
Figure 11.16: Asia-Pacific Oncology Precision Medicine Market, 2019-2030
Figure 11.17: Asia-Pacific: Market Dynamics
Figure 11.18: Asia-Pacific Oncology Precision Medicine Market (by Country), 2019-2030
Figure 11.19: China Oncology Precision Medicine Market, 2019-2030
Figure 11.20: Japan Oncology Precision Medicine Market, 2019-2030
Figure 11.21: Australia Oncology Precision Medicine Market, 2019-2030
Figure 11.22: India Oncology Precision Medicine Market, 2019-2030
Figure 11.23: Rest-of-Asia-Pacific Oncology Precision Medicine Market, 2019-2030
Figure 11.24: Latin America Oncology Precision Medicine Market, 2019-2030
Figure 11.25: Latin America: Market Dynamics
Figure 11.26: Latin America Global Oncology Precision Medicine Market (by Country), 2019 and 2030
Figure 11.27: Brazil Oncology Precision Medicine Market, 2019-2030
Figure 11.28: Mexico Oncology Precision Medicine Market, 2019-2030
Figure 11.29: Rest-of-LATAM Oncology Precision Medicine Market, 2019-2030
Figure 11.30: Rest-of-the-World Oncology Precision Medicine Market, 2019-2030
Figure 12.1: Abbott Laboratories: Overall Product Offerings
Figure 12.2: Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.3: Abbott Laboratories: Net Revenue (by Business Segment), 2017-2019
Figure 12.4: Abbott Laboratories: Net Revenue (by Region), 2017-2019
Figure 12.5: Abbott Laboratories: Research and Development Expense, 2017-2019
Figure 12.6: Abbott Laboratories: SWOT Analysis
Figure 12.7: Agilent Technologies, Inc.: Overall Product Offerings
Figure 12.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.9: Agilent Technologies, Inc.: Net Revenue (by Business Segment), 2017-2019
Figure 12.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.11: Agilent Technologies, Inc.: Research and Development Expense, 2017-2019
Figure 12.12: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.13: Almac Group Ltd.: Overall Product Offerings
Figure 12.14: Almac Group Ltd.: SWOT Analysis
Figure 12.15: ANGLE plc: Overall Financials, 2017-2019
Figure 12.16: ANGLE plc: Revenue (by Region), 2018-2019
Figure 12.17: ANGLE plc R&D Expenditure, 2017-2019
Figure 12.18: ANGLE plc: SWOT Analysis
Figure 12.19: ASURAGEN, INC.: Overall Product Offerings
Figure 12.20: ASURAGEN INC.: SWOT Analysis
Figure 12.21: BGI Group.: Overall Product Portfolio
Figure 12.22: BGI Group: SWOT Analysis
Figure 12.23: Bio-Rad Laboratories, Inc: Overall Product Offerings
Figure 12.24: Bio-Rad Laboratories, Inc: Overall Financials, 2017-2019
Figure 12.25: Bio-Rad Laboratories, Inc: Revenue (by Business Segment), 2017-2019
Figure 12.26: Bio-Rad Laboratories, Inc: Revenue (by Region), 2017-2019
Figure 12.27: Bio-Rad Laboratories, Inc. R&D Expenditure, 2017-2019
Figure 12.28: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 12.29: bioMérieux S.A.: Overall Product Portfolio
Figure 12.30: bioMérieux S.A.: Overall Financials, 2017-2019
Figure 12.31: bioMérieux S.A.: Revenue (by Segment), 2017-2019
Figure 12.32: bioMérieux S.A.: Revenue (by Region), 2018 and 2019
Figure 12.33: bioMérieux S.A.: SWOT Analysis
Figure 12.34: Bristol-Myers Squibb Company: Overall Product Portfolio
Figure 12.35: Bristol-Myers Squibb Company: Overall Financials, 2017-2019
Figure 12.36: Bristol-Myers Squibb Company R&D Expenditure, 2017-2019
Figure 12.37: Bristol-Myers Squibb Company: SWOT Analysis
Figure 12.38: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 12.39: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 12.40: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 12.41: Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 12.42: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 12.43: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 12.44: Gilead Sciences, Inc.: Overall Product Portfolio
Figure 12.45: Gilead Sciences, Inc.: Overall Financials, 2017-2019
Figure 12.46: Gilead Sciences, Inc.: R&D Expenditure, 2017-2019
Figure 12.47: Gilead Science, Inc.: SWOT Analysis
Figure 12.48: Illumina, Inc.: Overall Product Portfolio
Figure 12.49: Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.50: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.51: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.52: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.53: Illumina, Inc.: SWOT Analysis
Figure 12.54: Konica Minolta, Inc.: Overall Product Portfolio
Figure 12.55: Konica Minolta, Inc.: Overall Financials, 2017-2019
Figure 12.56: Konica Minolta, Inc.: Revenue (by Region), 2017-2019
Figure 12.57: Konica Minolta, Inc.: Research and Development Expense, 2017-2019
Figure 12.58: Konica Minolta, Inc.: SWOT Analysis
Figure 12.59: Laboratory Corporation of America Holdings.: Overall Product Portfolio
Figure 12.60: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 12.61: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 12.62: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 12.63: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 12.64: MDx Health, Inc.: Overall Financials, 2017--2019
Figure 12.65: MDx Health, Inc.: SWOT Analysis
Figure 12.66: Myriad Genetics, Inc.: Product Portfolio
Figure 12.67: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.68: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.69: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.70: Myriad Genetics, Inc.: SWOT Analysis
Figure 12.71: Novartis AG: Overall Product Portfolio
Figure 12.72: Novartis AG: Overall Financials, 2017-2019
Figure 12.73: Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 12.74: Novartis AG: Net Revenue (by Region), 2017-2019
Figure 12.75: Novartis AG: R& D Expense, 2017-2019
Figure 12.76: Novartis AG: SWOT Analysis
Figure 12.77: OPKO Health, Inc.: Overall Product Portfolio
Figure 12.78: OPKO Health, Inc.: Overall Financials, 2017-2019
Figure 12.79: OPKO Health, Inc: Net Revenue (by Business Segment), 2017-2019
Figure 12.80: OPKO Health, Inc.: Net Revenue (by Region), 2017-2019
Figure 12.81: OPKO Health, Inc.: Research and Development Expense, 2017-2019
Figure 12.82: OPKO Health, Inc.: SWOT Analysis
Figure 12.83: Pacific Biosciences of California, Inc.: Overall Product Portfolio
Figure 12.84: Pacific Biosciences of California, Inc.: Overall Financials, 2017-2019
Figure 12.85: Pacific Biosciences of California, Inc.: Revenue (by Segment), 2017-2019
Figure 12.86: Pacific Biosciences of California, Inc.: Revenue (by Region), 2017-2019
Figure 12.87: Pacific Biosciences of California, Inc.: R&D Expenditure, 2017-2019
Figure 12.88: Pacific Biosciences of California, Inc.: SWOT Analysis
Figure 12.89: Quest Diagnostics Incorporated: Overall Product Offerings
Figure 12.90: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 12.91: Quest Diagnostics Incorporated: Revenue (by Business Segment), 2017-2019
Figure 12.92: Quest Diagnostics Incorporated: SWOT Analysis
Figure 12.93: QIAGEN N.V.: Overall Product Portfolio
Figure 12.94: QIAGEN N.V.: Overall Financials, 2017-2019
Figure 12.95: QIAGEN N.V.: Revenue (by Segment), 2017-2019
Figure 12.96: QIAGEN N.V.: Revenue (by Region), 2017-2019
Figure 12.97: QIAGEN N.V.: R&D Expenditure, 2017-2019
Figure 12.98: QIAGEN N.V.: SWOT Analysis
Figure 12.99: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 12.100: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
Figure 12.101: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2017-2019
Figure 12.102: Thermo Fisher Scientific Inc.: Revenue (by Region), 2017-2019
Figure 12.103: Thermo Fisher Scientific Inc.: R&D Expenditure, 2017-2019
Figure 12.104: Thermo Fisher Scientific Inc.: SWOT Analysis